158P - Targeting efficiency and biodistribution of EGFR-conjugated mesoporous silica nanoparticles for cisplatin delivery in nude mice with lung cancer
|Date||30 September 2012|
|Event||ESMO Congress 2012|
|Session||Poster presentation II|
|Topics|| Basic Science
Lung and other Thoracic Tumours
Lung cancer is the most malignant cancer today; in order to develop an effective drug delivery system for lung cancer therapy In this study, an efficient approach for tumor-targeted drug delivery was developed with non-small cell lung cancer as the targeting vehicle and a mesoporous silica nanoparticle as the drug carrier. A mesoporous silica nanoparticle-cisplatin drug delivery system was efficiently anchored to non-small cell lung cancer by specific EGFR recognitions at the cytomembrane interface without any cell preconditioning. By the in vitro cell culture test, EGFR-MSN-cisplatin resulted in higher entrance efficiency on adenocarcinoma cells (A549) than that on normal lung cells (L-132) because A549 possessed greater amounts of EGFR. High levels of nanoparticles were uptake to each MSCLC cell with high cell viability and tumor-tropic ability. The intracellular retention time of the MSN was no less than 48 h, which is sufficient for cell-directed tumor-tropic delivery. In vivo experiments proved that the burdened NSCLC can track down the more efficiently and deliver cisplatin with wider distribution and longer retention lifetime in tumor tissues compared with free cisplatin and EGFR-MSN-cisplatin. The increased and prolonged cisplatin intratumoral distribution further contributed to significantly enhanced tumor-cell apoptosis. This strategy has potential to be developed as a robust and generalizable method for targeted tumor therapy with high efficiency and low systematic toxicity.Disclosure
All authors have declared no conflicts of interest.